Quick Answer
Arcus Biosciences, Inc. reported Operating Income Loss of -$386.00 million for the year ending 2025.
- Arcus Biosciences, Inc. showed a decrease of -17.0% in Operating Income Loss from 2024 to 2025.
- This data is from Arcus Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$7.30 million | Q2 2017: -$9.66 million | Q3 2017: -$23.13 million | Q1 2018: -$13.33 million | Q2 2018: -$15.90 million | Q3 2018: -$12.15 million | Q1 2019: -$18.77 million | Q2 2019: -$29.16 million | Q3 2019: -$23.25 million | Q1 2020: -$28.40 million | Q2 2020: -$45.38 million | Q3 2020: $1.55 million | Q1 2021: -$72.75 million | Q2 2021: -$76.14 million | Q3 2021: -$78.14 million | Q1 2022: -$67.00 million | Q2 2022: -$69.00 million | Q3 2022: -$70.00 million | Q1 2023: -$86.00 million | Q2 2023: -$83.00 million | Q3 2023: -$80.00 million | Q1 2024: -$16.00 million | Q2 2024: -$106.00 million | Q3 2024: -$105.00 million | Q1 2025: -$122.00 million | Q2 2025: -$8.00 million | Q3 2025: -$142.00 million.
- Over the full 10 years of available data (2016 to 2025), Arcus Biosciences, Inc.'s Operating Income Loss has declined by 2,023.0%.
- Historical annual values: Fiscal year 2025: -$386.00 million | Fiscal year 2024: -$330.00 million | Fiscal year 2023: -$340.00 million | Fiscal year 2022: -$280.00 million | Fiscal year 2021: $54.00 million | Fiscal year 2020: -$124.00 million | Fiscal year 2019: -$88.71 million | Fiscal year 2018: -$54.86 million | Fiscal year 2017: -$53.44 million | Fiscal year 2016: -$18.18 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: